HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer

Pathobiology

Volumn 77, Issue 1, 2010, Pages 17-23

  Moriwaka, Yukiko ^a   Luo, Yi ^a   Ohmori, Hitoshi ^a   Fujii, Kiyomu ^a   Tatsumoto, Naokuni ^b   Sasahira, Tomonori ^a   Kuniyasu, Hiroki ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Miyoshi Central Hospital   (Japan)

Author keywords

Colorectal cancer; HMGB1; Liver metastasis; Lymph vessel density; Macrophages; Nodal metastasis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE; LYMPH NODE METASTASIS; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN SECRETION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; COLORECTAL NEOPLASMS; FEMALE; HMGB1 PROTEIN; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MACROPHAGES; MALE; MIDDLE AGED;

EID: 77749326593     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000272950     Document Type: Article

References (37)

1. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458.
2. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW: Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002; 62: 7042-7049.
3. Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR, et al: Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146-1151. (Pubitemid 26274608)
4. Kuniyasu H, Sasaki T, Sasahira T, Ohmori H, Takahashi T: Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 2004; 71: 129-136.
5. Huttunen HJ, Rauvala H: Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J Intern Med 2004; 255: 351-366.
6. Yang H, Wang H, Tracey KJ: HMG-1 rediscovered as a cytokine. Shock 2001; 15: 247-253.
7. Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, Fujii K, et al: High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008; 99: 1806-1812.
8. Czura CJ, Wang H, Tracey KJ: Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001; 7: 315-321.
9. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A: HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994; 91: 10394-10398.
10. Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M, et al: Amphoterin, the 30-kDa protein in a family of HMG1- type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 1993; 268: 19726-19738.
11. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096-40105.
12. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
13. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al: Expression of receptors for advanced glycation endproducts (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196: 163-170.
14. Kuniyasu H, Chihara Y, Kondo H: Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003; 104: 722-727.
15. Kuniyasu H, Chihara Y, Takahashi T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003; 10: 445-448.
16. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R: Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003; 10: 1863-1868.
17. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K, et al: The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007; 450: 287-295. (Pubitemid 46376559)
18. Sasahira T, Kirita T, Bhawal UK, Yamamoto K, Ohmori H, Fujii K, et al: Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology 2007; 51: 166-172. (Pubitemid 47083983)
19. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
20. Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H: Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005; 166: 751-760.
21. Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, Tatsumoto N, et al: Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 2009; 76: 155-162.
22. Kuniyasu H, Yasui W, Shinohara H, Yano S, Ellis LM, Wilson MR, et al: Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol 2000; 157: 1523-1535.
23. Sasahira T, Sasaki T, Kuniyasu H: Interleukin-15 and transforming growth factor - are associated with depletion of tumor-associated macrophages in colon cancer. J Exp Clin Cancer Res 2005; 24: 69-74.
24. Suda K, Kitagawa Y, Ozawa S, Saikawa Y, Ueda M, Abraham E, et al: Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery? Dis Esophagus 2006; 19: 5-9.
25. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-583.
26. van der Bij GJ, Oosterling SJ, Meijer S, Beelen RH, van Egmond M: Therapeutic potential of Kupffer cells in prevention of liver metastases outgrowth. Immunobiology 2005; 210: 259-265.
27. Timmers M, Vekemans K, Vermijlen D, Asosingh K, Kuppen P, Bouwens L, et al: Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis. Int J Cancer 2004; 112: 793-802.
28. Khatib AM, Auguste P, Fallavollita L, Wang N, Samani A, Kontogiannea M, et al: Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 2005; 167: 749-759.
29. Nagata H, Arai T, Soejima Y, Suzuki H, Ishii H, Hibi T: Limited capability of regional lymph nodes to eradicate metastatic cancer cells. Cancer Res 2004; 64: 8239-8248.
30. Martens JH, Kzhyshkowska J, Falkowski- Hansen M, Schledzewski K, Gratchev A, Mansmann U, et al: Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis. J Pathol 2006; 208: 574-589.
31. Ichii S, Imai Y, Irimura T: Initial steps in lymph node metastasis formation in an experimental system: possible involvement of recognition by macrophage C-type lectins. Cancer Immunol Immunother 2000; 49: 1-9.
32. Gannon PO, Alam Fahmy M, Begin LR, Djoukhadjian A, Filali-Mouhim A, Lapointe R, et al: Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate 2006; 66: 1710-1720.
33. Schmidt AM, Stern DM: RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000; 11: 368-375.
34. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al: RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45(suppl 3):S77-S80.
35. Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, Kato I, et al: Roles of the AGERAGE system in vascular injury in diabetes. Ann NY Acad Sci 2000; 902: 163-170.
36. Tesch GH: Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol 2007; 34: 1016-1019.
37. Sobin LH, Wittekind C (eds): UICC TNM Classification of Malignant Tumors, ed 6. New York, Wiley, 2003.